Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Primary Purpose
Solid Tumors Harboring NTRK Fusion
Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Selitrectinib (BAY2731954)
Sponsored by

About this trial
This is an expanded access trial for Solid Tumors Harboring NTRK Fusion focused on measuring Metastatic cancer, Advanced cancer, Neurotrophic tyrosine receptor kinase (NTRK), NTRK1, NTRK2, NTRK3, Fusion Positive, Children, Loxo-195
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
- Previous treatment with a kinase inhibitor with known activity on TRK inhibition
- Unable to participate in an ongoing selitrectinib clinical trial
- Medically suitable for treatment with selitrectinib
Exclusion Criteria:
- Currently enrolled in an ongoing clinical study with a TRK inhibitor
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03206931
Brief Title
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Official Title
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.
Study Type
Expanded Access
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
4. Oversight
5. Study Description
Brief Summary
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors Harboring NTRK Fusion
Keywords
Metastatic cancer, Advanced cancer, Neurotrophic tyrosine receptor kinase (NTRK), NTRK1, NTRK2, NTRK3, Fusion Positive, Children, Loxo-195
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Selitrectinib (BAY2731954)
Other Intervention Name(s)
Loxo-195
Intervention Description
Selitrectinib is administered as capsules or liquid formulation.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Eligibility Criteria
Inclusion Criteria:
Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
Previous treatment with a kinase inhibitor with known activity on TRK inhibition
Unable to participate in an ongoing selitrectinib clinical trial
Medically suitable for treatment with selitrectinib
Exclusion Criteria:
Currently enrolled in an ongoing clinical study with a TRK inhibitor
12. IPD Sharing Statement
Learn more about this trial
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
We'll reach out to this number within 24 hrs